A novel, rapid strategy to form dendritomas from human dendritic cells and hepatocellular carcinoma cell line HCCLM3 cells using mature dendritic cells derived from human peripheral blood CD14+ monocytes within 48 hours of in vitro culture

Figure 1 FACS analysis of activation markers on FastDCs and novel dendritomas. A: Expression of DCs activation markers on FastDCs determined by FACS. B: DCs activation markers expressing on novel dendritomas determined by FACS.

Figure 2 Fusion efficiency analysis by FACS. A: Control group (mixture): 3.19% dual-fluorescent cells. B: Fusion group: 27.46% dual-fluorescent cells.

Figure 3 Images of novel dendritomas and HCCLM3 cells under confocal laser scanning microscopy. A: Red tumor and dendritoma cells. B: Green dendritoma cells. C: One dendritoma cell with two blue nuclei and one tumor cell with one nucleus. D: One dendritoma cell (right) characteristic of a dual-fluores-cent cell with two blue nuclei while one red fluorescent tu-mor cell (left) with one nucleus.